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Purpose: Liver resection with colorectal liver metastasis widely accepted and has 
been considered safe and effective therapeutic option. However, the role of liver 
resection in breast cancer with liver metastasis is still controversial. Therefore, we 
reviewed the outcome of liver resection in breast cancer patients with liver metas-
tases in a single hospital experiences. Materials and Methods: Between January 
1991 and December 2006, 2176 patients underwent breast cancer surgery in 
Gangnam Severance Hospital. Among these patients, 110 cases of liver metastases 
were observed during follow-up and 13 of these patients received liver resection 
with potential feasibility to achieve an R0 resection. Results: The median time in-
terval between initial breast cancer and detection of liver metastasis was 62.5 
months (range, 13-121 months). The 1-year and 3-year overall survival rates of the 
13 patients with liver resection were 83.1% and 49.2%, respectively. The 1-year 
and 3-year overall survival rates of patients without extrahepatic metastasis were 
83.3% and 66.7% and those of patients with extrahepatic metastasis were 80.0% 
and 0.0%, respectively (p=0.001). Conclusion: Liver resection for metastatic 
breast cancer results in improved patient survival, particularly in patients with soli-
tary liver metastasis and good general condition.
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INTRODUCTION
Because many doctors consider liver metastasis from malignant cancer as a sys-
temic recurrence rather than a local recurrence, their therapeutic aim is only to im-
prove the quality of life using conservative management. However, liver resection 
in patients with colorectal liver metastasis has now become widely accepted and 
has been shown to be a safe and effective therapeutic option in several reports.1,2 In 
contrast to metastasis from colorectal cancer, non-colorectal liver metastasis is 
only considered for surgical resection in selected cases. 
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ware, Version 16.0 (SPSS Inc., Chicago, IL, USA). Cate-
gorical variables were analyzed using the χ2 or Fisher’s ex-
act test, and continuous variables were analyzed using 
either a Student’s t-test or Mann-Whitney U rank tests. A p-
value less than 0.05 was considered statistically significant. 
Survival curves were constructed and compared by the Ka-
plan-Meier method and the log-rank test, respectively.
RESULTS
 
Patient characteristics
During the study period, a total of 110 patients were diag-
nosed with breast cancer with liver metastasis: 91 patients 
(83%) with multi-organ metastasis, including the liver, and 
19 (17%) patients with isolated liver metastasis. Among the 
110 patients with liver metastasis, 13 received liver resec-
tion with potential feasibility to achieve an R0 resection. 
The mean age of the 13 patients was 51.0±9.4 years (range 
39-64 years) and were all female.
All 13 patients underwent surgery for breast cancer in-
volving either conservative breast surgery or radical mas-
tectomy. The pathology of breast cancer was infiltrating 
ductal carcinoma in 12 patients (92.3%) and mucinous car-
cinoma in one patient (7.7%). The histological grade classi-
fication of breast cancer was well differentiated in seven 
patients (53.8%), moderately differentiated in three patients 
(23.1%), and poorly differentiated in three patients (23.1%). 
The T stage of breast cancer was T1 in four patients (30.8%), 
T2 in seven patients (53.8%), T3 in one patient (7.7%), and 
T4 in one patient (7.7%). The initial N stage of breast cancer 
was N0 in five patients (38.5%), N1 in two patients (15.3%), 
N2 in five patients (38.5%), and N3 in one patient (7.7%). 
The hormone receptor and HER2 status of the breast cancer 
was available for all patients. Six patients had estrogen (ER) 
and progesterone (PR) positive tumors, one was ER+/PR-, 
one was ER-/PR+ and five were ER-/PR-. Five patients were 
HER2-positive (38.5%). All patients received adjuvant ther-
apy after surgery for breast cancer depending on their hor-
mone receptor status and the stage. 
Patients were divided into two groups; solitary liver me-
tastasis and multi-organ metastasis including liver. Single 
liver metastasis was observed in seven (53.8%) patients, and 
multi-organ metastasis was detected in six (46.2%) patients. 
Clinicopathological characteristics of patients in the two 
groups are listed in Table 1 and 2. The median time interval 
between initial breast cancer and detection of liver metasta-
According to the Korea Cancer Center Registry, the rate 
of breast cancer is rapidly increasing and it ranks sixth in 
overall cancer incidence and second form of cancer among 
females in Korea.3 The prognosis of breast cancer has great-
ly improved as new medical imaging technologies and vari-
ous chemotherapeutic drugs have been developed. Howev-
er, liver metastases occur in 15% of breast cancer patients 
and these patients have a poor prognosis with an average 
survival period of less than 24 months, even if they receive 
aggressive systemic and hormone therapy.4-6  
Recently, liver resection-related mortality rates have large-
ly declined due to improved anesthesia, progression of sur-
gical techniques, and improvements in postoperative man-
agements. In addition, improved chemotherapy agents may 
reduce the number or size of liver metastases, resulting in 
favorable conditions before and after surgery. 
Some papers has reported that liver resection shows a ten-
dency to improve prognosis in selected patients.7-10 Howev-
er, the role of liver resection in breast cancer with liver me-
tastasis is still debatable. Therefore, we reviewed the outcome 
of patients with breast cancer with liver metastases after liv-
er resection in a single hospital experiences. 
MATERIALS AND METHODS
　　　
Patients 
Between January 1991 and December 2006, 2176 patients 
underwent breast cancer surgery in Gangnam Severance Hos-
pital, Yonsei University College of Medicine, Seoul, Korea. 
Among these patients, 110 cases of liver metastasis were ob-
served during follow-up. Of these, 13 patients received liver 
resection with potential feasibility to achieve an R0 resection. 
The patients were followed closely until December 30, 2011.
Ambulatory follow-up examinations of all patients were 
performed every 6 months for 5 years after the surgery and 
follow-up observation was performed every year subse-
quently. The following basic examinations were performed 
every 6 months after surgery: physical examination, radio-
logical examination (chest X-ray, ultrasound, and mammog-
raphy), and laboratory testing (general blood test, liver 
function test, and tumor marker test). Abdomen and chest 
computed tomography, bone scan and PET were routinely 
performed in all patients to check for systemic metastasis. 
Statistical analysis
All statistical analyses were performed using SPSS soft-
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tients. 
All patients with extrahepatic metastatic disease were 
treated with curative intent for their extrahepatic metastatic 
lesions. 
All patients received postoperative adjuvant chemothera-
py after liver resection. 
Surgical outcomes 
The 1-year and 3-year overall survival rates of the 13 patients 
with liver resection were 83.1% and 49.2%, respectively 
(Fig. 1). The 1-year and 3-year overall survival rates of pa-
tients without extrahepatic metastasis were 83.3% and 66.7% 
and those of patients with extrahepatic metastasis were 
80.0% and 0.0%, respectively (p=0.001) (Fig. 2). 
The 1-year and 3-year recurrence free survival rates after 
liver resection of the 13 patients were 50.0% and 16.7%, re-
spectively (Fig. 3). The 1-year and 3-year recurrence free 
survival rate after liver resection of patients without extrahe-
patic metastasis were 83.3% and 33.3% and those patients 
with extrahepatic metastasis were 33.3% and 0.0%, respec-
tively (p=0.023) (Fig. 4). 
sis excluding two patients with synchronous metastasis was 
62.5 months (range, 13-121 months).
Among patients with multi-organ metastasis, two (33.3%) 
had bone metastasis, two (33.3%) had metastasis in neck 
nodes, one (16.7%) had brain metastasis, and one (16.7%) 
had ovarian metastasis. 
Liver resection 
All patients received adjuvant therapy after surgery for breast 
cancer depending on their hormone receptor status and tumor 
stage. Two patients had synchronous metastases--liver metas-
tases at the time of the initial breast cancer diagnosis--and af-
ter six cycles of neo-adjuvant therapy, the breast cancer and 
metastatic liver lesions were both operated upon.
Nine patients (69.2%) received an open liver resection 
and four patients (30.8%) received laparoscopic liver re-
section. Major liver resection (three segments or more) 
was performed in one (7.7%) patient, minor resection 
(fewer than three segments) in four (30.8%) patients, and 
wedge resection in eight (61.5%) patients. Liver resection 
was combined with radiofrequency ablation in two pa-
Table 1. Clinical Characteristics of the Seven Patients Treated for Solitary Liver Metastasis from Breast Cancer
Case Sex
Age 
(yrs)
Status of breast cancer Status of liver metastasis
Postoperative 
chemotherapy
Survival 
(months)Pathology HG TNM
HR 
(ER/PR)
HER2 Site
Type of liver 
resection
1 F 44 IDC Mod T2N2M0 -/- - S4 Wedge resection Yes 39.3
2 F 39 IDC Well T1N0M0 +/+ - S4, 7, 8 Wedge resection+RFA Yes 54.4
3 F 62 IDC Well T1N0M0 +/+ - S6 Wedge resection Yes 50.2
4 F 61
Mucinous 
cancer
Well T2N0M0 +/- + S2, 3 Lateral sectionectomy Yes 15.6
5 F 60 IDC Well T2N2M0 -/- - S3 Wedge resection Yes 17.6
6 F 49 IDC Poor T4N2M0 +/+ - S5 Wedge resection Yes 15.2
7 F 39 IDC Poor T1N0M0 -/+ - S3 Lateral sectinectomy Yes 57.9
IDC, infiltrating ductal carcinoma; HG, histologic grade; HR, hormone receptor; RFA, radiofrequency ablation; ER, estrogen; PR, progesterone.
Table 2. Clinical Characteristics of the Six Patients Treated for Extrahepatic and Liver Metastasis from Breast Cancer 
Case Sex
Age 
(yrs)
Status of breast cancer
Extrahepatic 
metastasis
Status of liver metastasis
Postoperative 
chemotherapy
Survival 
(months)Pathology HG TNM
HR 
(ER/PR)
HER2 Site
Type of liver 
resection
1 F 46 IDC Mod T2N2M0 -/- + Neck node S4, 5 Wedge resection Yes 13.1
2 F 45 IDC Well T3N3M0 +/+ - Ovary S2, 4, 7, 8 Wedge resection Yes 12.5
3 F 41 IDC Moderate T2N2M0 +/+ + Bone S6, 7
Right posterior 
  sectionectomy
Yes 25.0
4 F 54 IDC Well T2N1M0 -/- + Brain S4 Wedge resection Yes   7.1
5 F 64 IDC Well T2N2M0 +/+ - Bone S3, 7, 8
Lateral sectionectomy 
  +RFA
Yes 11.8
6 F 60 IDC Poor T1N0M0 -/- + Neck node S5 Lateral sectionectomy Yes   7.6
IDC, infiltrating ductal carcinoma; HG, histologic grade; HR, hormone receptor; RFA, radiofrequency ablation; ER, estrogen; PR, progesterone.
Liver Resection for Breast Cancer Liver Metastasis
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014 561
and postoperative morbidity and mortality rates have de-
creased after operation, attempts of liver resection from 
breast cancer started in the 1980s. Elias, et al.7 first reported 
that liver resection in patients with metastatic breast cancer 
could lengthen patient survival compared with conservative 
management. Nevertheless, the role of surgical treatment 
for liver metastasis from breast cancer has not yet been 
clearly defined. 
Many studies have reported that median survival for liver 
resection in breast cancer ranges between 24 and 60 months 
and 5-year survival rates are between 21% and 60%.16-19 In 
the present study, the average median survival was 57.9 
months, and the 3-year survival rate was 59.3%. This repre-
sents an improved overall survival rate compared with pa-
tients that received systemic chemotherapy treatment.20-22
Some reports showed that age, estrogen and HER2 recep-
tor status of the primary tumor, number of metastasis, and 
resection margins are significant prognostic factors.9,10,17-19,23 
However, we could not analyze the prognostic factors after 
DISCUSSION
Recurrence rates after breast cancer surgery are 30-40%, 
and mainly involve bone metastases. After bone and lung 
metastases, liver metastases represent 40% of total breast 
cancer recurrence;11 bone metastasis was also the most fre-
quent in this study and liver metastasis ranked third in total 
recurrences.
Nonetheless, many doctors consider liver metastasis from 
breast cancer as systemic recurrence. Therefore, their aim is 
only to improve the quality of the patient’s life using allevia-
tion therapy rather than improving survival rates. Recently, 
patients with liver metastasis from breast cancer have shown 
improved survival rates due to improvements in anticancer 
drugs.12-14 However, these are not satisfactory long-term sur-
vival rates and the average overall survival time is reported 
to be only 15 months.15 
As surgical techniques for liver resection have improved 
Fig. 1. Overall survival rate after hepatic resection for breast cancer pa-
tients with liver metastasis.
Fig. 2. Overall survival rate following hepatic resection according to status 
of extrahepatic metastasis. 
Fig. 3. Recurrence free survival rate after hepatic resection for breast can-
cer patients with liver metastasis.
Fig. 4. Recurrence free survival rates following hepatic resection accord-
ing to status of extrahepatic metastasis. 
Months
Months
Months
Months
0.0
0.0
0.0
0.0
0.2
0.2
0.2
0.2
0.4
0.4
0.4
0.4
0.6
0.6
0.6
0.6
0.8
0.8
0.8
0.8
1.0
1.0
1.0
1.0
Ov
er
al
l s
ur
viv
al
 ra
te
 (%
)
Ov
er
al
l s
ur
viv
al
 ra
te
 (%
)
Re
cu
rre
nc
e 
fre
e 
su
rv
iva
l r
at
e 
(%
)
Re
cu
rre
nc
e 
fre
e 
su
rv
iva
l r
at
e 
(%
)
0.00
0.00
0.00
0.00
12.00
12.00
12.00
12.00
24.00
24.00
24.00
24.00
36.00
36.00
36.00
36.00
48.00
48.00
48.00
48.00
60.00
60.00
60.00
60.00
Extrahepatic metastasis
Single liver metastasis
p=0.001
Extrahepatic metastasis
Single liver metastasis
p=0.023
Jee Ye Kim, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014562
after adjuvant treatment in premenopausal and perimenopausal 
women: patterns and prognoses. J Clin Oncol 1988;6:89-97.
9. Neri A, Marrelli D, Pedrazzani C, Caruso S, De Stefano A, Mari-
ani F, et al. Prognostic relevance of proliferative activity evaluated 
by Mib-1 immunostaining in node negative breast cancer. Eur J 
Surg Oncol 2008;34:1299-303.
10. Konecny GE, Thomssen C, Lück HJ, Untch M, Wang HJ, Kuhn 
W, et al. Her-2/neu gene amplification and response to paclitaxel 
in patients with metastatic breast cancer. J Natl Cancer Inst 2004; 
96:1141-51.
11. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg 
Oncol 1983;23:175-80.
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18. Hoffmann K, Franz C, Hinz U, Schirmacher P, Herfarth C, Eich-
baum M, et al. Liver resection for multimodal treatment of breast 
cancer metastases: identification of prognostic factors. Ann Surg 
Oncol 2010;17:1546-54.
19. Weitz J, Blumgart LH, Fong Y, Jarnagin WR, D’Angelica M, Har-
rison LE, et al. Partial hepatectomy for metastases from non-
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269-76.
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Surgical treatment of hepatic metastases from breast cancer. Breast 
Cancer Res Treat 2000;59:177-84.
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al. Randomized trial of high-dose chemotherapy with autologous 
peripheral-blood stem-cell support compared with standard-dose 
chemotherapy in women with metastatic breast cancer: NCIC 
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liver resection because of the small number of patients in 
our study. 
In this study, the surgical indication of liver metastasis was 
restricted to cases where an extrahepatic lesion could be con-
trolled by local treatment and no other distant metastases 
were present. Nonetheless, we demonstrated that the pres-
ence of extrahepatic metastasis lesions was a significant 
prognostic factor after liver resection. In our results, after liv-
er resection of patients with extrahepatic metastasis, the 1- 
and 3-year survival rates were 60.0% and 20.0%, respective-
ly. Therefore, even when extrahepatic metastasis is present, if 
the systemic condition of the patient is satisfactory and if 
cure of the extrahepatic lesion is possible, we think that sur-
gical treatment of the liver lesions should be considered. 
It is possible that the treatment outcome of patients with 
liver metastasis may have been overestimated in this study 
because it is a retrospective study with a limited number of 
cases. Nonetheless, although this study contains a small 
number of patients and has limitations, it suggests that sur-
gery in patients with solitary liver metastasis results in a 
promising good prognosis. 
In conclusion, liver resection for metastatic breast cancer 
results in improved patient survival, particularly in patients 
with solitary liver metastasis and good general condition. 
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